Key result
Oral sildenafil for 3 months reduced mean pulmonary artery pressure from 55.8 to 50.4 mmHg and pulmonary vascular resistance in pulmonary hypertension.
Why the study?
Does sildenafil improve pulmonary haemodynamics and clinical status in patients with pulmonary hypertension?
Does sildenafil improve pulmonary haemodynamics and clinical status in patients with pulmonary hypertension?
Sildenafil improves pulmonary hemodynamics and exercise capacity in patients with pulmonary hypertension over a 3-month period.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for sildenafil in pulmonary hypertension; leaves open efficacy and safety pending randomized trials.
AIM: The treatment of patients with pulmonary arterial hypertension remains a challenge. We set out to investigate the use of sildenafil, a selective inhibitor of phosphodiesterase type 5, in patients with this disease. METHODS AND RESULTS: Ten patients (8 females, mean age 34.5+/-3.3 years) with pulmonary hypertension underwent right heart catheterisation with vasodilator testing using incremental doses of intravenous sildenafil without adverse events. All patients were subsequently commenced on oral sildenafil 50 mg t.d.s. Nine patients had repeat right heart catheterisation 3 months after the commencement of oral therapy. There was a significant reduction in mean pulmonary artery pressure (from 55.8+/-5.9 to 50.4+/-6.1 mmHg, p=0.038 ) and pulmonary vascular resistance (from 10.1+/-1.7 to 8.6+/-1.5 Wood units, p=0.009 ), and an increase in cardiac output (from 4.7+/-0.3 to 5.0+/-0.4 l/min, p=0.15 ). Furthermore, there was a significant increase in the 6-minute walk test, a mean of 112 m. In response to a quality-of-life questionnaire, patients indicated marked clinical improvement on sildenafil. Sildenafil was discontinued in 1 patient due to a transient visual disturbance. The only patient previously awaiting transplantation was removed from the active transplantation list. CONCLUSIONS: Sildenafil is well tolerated in its intravenous and oral forms and appears to improve both pulmonary haemodynamics and the clinical status of patients with pulmonary hypertension after 3 months of oral therapy.
No takes yet. Share an insight, caveat, or question.
Ghada Mikhail (2004) studied pulmonary hypertension (n=10). Sildenafil was evaluated on mean pulmonary artery pressure (p=0.038). Oral sildenafil for 3 months reduced mean pulmonary artery pressure from 55.8 to 50.4 mmHg and pulmonary vascular resistance in pulmonary hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: